Llanos Adana A M, Chandwani Sheenu, Bandera Elisa V, Hirshfield Kim M, Lin Yong, Ambrosone Christine B, Demissie Kitaw
Department of Epidemiology, Rutgers School of Public Health, 683 Hoes Lane West, Room 211, Piscataway, NJ, 08854, USA.
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Cancer Causes Control. 2015 Dec;26(12):1737-50. doi: 10.1007/s10552-015-0667-4. Epub 2015 Sep 16.
This study examines the factors distinguishing breast cancer (BC) subtypes.
We examined subtypes in 629 women with invasive BC, diagnosed from 2006 to 2012, and enrolled in an epidemiological study in New Jersey. Using molecular characteristics from pathology reports, BCs were categorized as luminal A, luminal B, non-luminal HER2-expressing, or triple-negative breast cancer (TNBC) subtypes. Multinomial logistic models (luminal A as referent) were used to describe BC subtype associations.
Women with luminal B tumors were more likely to be younger at diagnosis [odds ratio (OR) 1.8, 95% confidence interval (CI) 1.0-3.4] and to have higher-grade (OR 2.6, 95% CI 1.5-4.7), larger (OR 1.9, 95% CI 1.0-3.6), and Ki67-positive tumors (OR 2.1, 95% CI 1.1-4.0). Women with non-luminal HER2-expressing BCs were more likely to have higher-grade tumors (OR 14.5, 95% CI 5.3-39.7). Women with TNBCs were more likely to be African-American (OR 1.9, 95% CI 1.0-3.4) and to have higher-grade (OR 9.7, 95% CI 5.1-18.4), larger (OR 2.2, 95% CI 1.0-4.8), and Ki67-positive (OR 2.9, 95% CI 1.6-5.2) tumors. Notably, compared to the luminal A subtype, luminal B, non-luminal HER2-expressing, and triple-negative subtypes were more frequently self-detected; however, these associations were attenuated in multivariable models.
These findings suggest that some BC subtypes were associated with features denoting more aggressive phenotypes, namely higher grade, larger size, and Ki67 positivity, and possibly patient self-detection among some women. These findings highlight a need for enhanced screening, particularly among younger women, racial/ethnic minorities, and lower socioeconomic subgroups.
本研究探讨区分乳腺癌(BC)亚型的因素。
我们对2006年至2012年确诊的629例浸润性乳腺癌女性患者进行了亚型研究,这些患者均参加了新泽西州的一项流行病学研究。利用病理报告中的分子特征,将乳腺癌分为腔面A型、腔面B型、非腔面HER2过表达型或三阴性乳腺癌(TNBC)亚型。采用多项逻辑模型(以腔面A型为参照)来描述乳腺癌亚型之间的关联。
腔面B型肿瘤患者诊断时年龄较轻的可能性更大[比值比(OR)为1.8,95%置信区间(CI)为1.0 - 3.4],肿瘤分级较高(OR为2.6,95% CI为1.5 - 4.7)、肿瘤更大(OR为1.9,95% CI为1.0 - 3.6)以及Ki67阳性肿瘤的可能性更大(OR为2.1,95% CI为1.1 - 4.0)。非腔面HER2过表达型乳腺癌患者肿瘤分级较高的可能性更大(OR为14.5,95% CI为5.3 - 39.7)。三阴性乳腺癌患者更可能是非裔美国人(OR为1.9,95% CI为1.0 - 3.4),且肿瘤分级较高(OR为9.7,95% CI为5.1 - 18.4)、肿瘤更大(OR为2.2,95% CI为1.0 - 4.8)以及Ki67阳性(OR为2.9,95% CI为1.6 - 5.2)的可能性更大。值得注意的是,与腔面A型亚型相比,腔面B型、非腔面HER2过表达型和三阴性亚型更常通过自我检测发现;然而,在多变量模型中这些关联有所减弱。
这些发现表明,某些乳腺癌亚型与更具侵袭性的表型特征相关,即更高分级、更大尺寸和Ki67阳性,并且在一些女性中可能与患者自我检测有关。这些发现凸显了加强筛查的必要性,特别是在年轻女性、种族/族裔少数群体和社会经济地位较低的亚组中。